You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The company's lead product is a software platform that uses a patient's pharmacogenetic and other medical data to help personalize drug selection.
The firm's lead product is a blood-based assay, called Alibrex, which uses PCR technology to monitor stage IV solid tumor cancer therapy.
The company plans to use the funds to support development of an early cancer detection test and expansion of its CDx sales force.
The firm has developed a microbiome analytics platform for supply chain management that combines next-generation sequencing and artificial intelligence.
The genome informatics company will apply the new capital to deploy the DNAnexus Apollo platform for multi-omics data science exploration, analysis, and discovery.
GreenLight Biosciences is using a proprietary cell-free RNA production technology to develop RNA-based products for the agricultural market.
The round was led by Meritech Capital, with participation from Fidelity and Wells Fargo, and brings the company's total financing to date to $243 million.
The San Diego-based company plans to use the funding to support the development of its molecular electronics-based DNA sequencing technology.
With this latest financing round, the Cambridge, UK-based developer of genomic data management software has raised a total of $3.2 million to date.
The startup plans to use the funds to scale its single-cell DNA analysis technology for blood-based cancer research and expand into CRISPR applications.
Public health experts call for a transparent COVID-19 vaccine approval process in a letter; the Food and Drug Administration commissioner assures science-based approval.
The Verge reports that new gene-naming guidelines aim in part to avoid Excel-related name change confusion.
In Nature this week: tuatara genome sequence aids in understanding amniote evolution, and more.
According to the Guardian, UK virologists say in a letter to officials that their expertise has been pushed aside in COVID-19 response plans.